8-K: enGene Reports Q1 2024 Financial Results and Secures $200 Million Private Financing

enGene Holdings Inc. announced its first quarter 2024 financial results, highlighted by a $200 million private financing and progress in its pivotal Phase 2 LEGEND study for EG-70.

Summary

• enGene Holdings Inc. announced its financial results for the first quarter ended January 31, 2024.
• The company completed a $200 million oversubscribed private financing in February 2024, which is expected to extend the cash runway into 2027.
• The pivotal Phase 2 LEGEND study of EG-70 for bladder cancer remains on track, with interim data expected in mid-2024.
• Cash and cash equivalents were $85.6 million as of January 31, 2024, compared to $81.5 million as of October 31, 2023.
• Total operating expenses for the quarter were $10.8 million, compared to $4.6 million for the same period in 2023.
• The net loss attributable to common shareholders was $10.7 million, or $0.46 per share, compared to $8.6 million, or $13.29 per share, for the same period in 2023.

Sentiment

Score: 8

Explanation: The document is largely positive due to the successful private financing, progress in clinical trials, and extended cash runway. However, the increase in operating expenses and net loss, along with the CEO's resignation, temper the overall sentiment.

Positives

• The $200 million private financing provides significant capital to fund operations into 2027.
• The LEGEND study is on track, with interim data expected in mid-2024.
• The company has expanded its debt facility with Hercules Capital to up to $50 million.
• enGene has made key leadership hires, including a new CFO and CLO.
• The company has appointed a new board member and Audit Committee Chair.

Negatives

• Operating expenses increased significantly to $10.8 million for the quarter, compared to $4.6 million in the same period last year.
• The net loss attributable to common shareholders increased to $10.7 million, compared to $8.6 million for the same period in 2023.
• The company's CEO intends to resign due to personal family and health reasons.

Risks

• The company's ability to recruit and retain qualified personnel is a risk.
• There are risks associated with establishing clinical trial sites and enrolling patients.
• The company's ability to secure regulatory approval on anticipated timelines is a risk.
• The company's actual results may differ materially from forward-looking statements due to various factors.

Future Outlook

enGene expects its existing cash and cash equivalents, along with the proceeds from the recent private financing, to fund operations into 2027. The company plans to complete the LEGEND study, file a BLA in the first quarter of 2026, and pursue pipeline expansion.

Management Comments

• Jason Hanson, Chief Executive Officer of enGene, stated that the company is moving closer to realizing its vision of mainstreaming genetic medicines.
• Mr. Hanson also noted the encouraging safety profile and 73% complete response rate from the Phase 1 data for EG-70.
• The company believes it is well-positioned to complete the ongoing pivotal-stage LEGEND study.

Industry Context

This announcement is significant in the context of the growing interest in genetic medicines and non-viral delivery systems. enGene's progress with EG-70 and its proprietary DDX platform positions it as a notable player in the field of bladder cancer treatment.

Comparison to Industry Standards

• The 73% complete response rate in the Phase 1 trial of EG-70 is very promising compared to standard treatments for BCG-unresponsive NMIBC, which often have lower response rates.
• The $200 million private financing is a substantial amount for a clinical-stage biotech company, indicating strong investor confidence.
• The company's cash runway extending into 2027 is a positive sign, as many biotech companies face funding challenges.
• Comparable companies in the NMIBC space include CG Oncology, which is also developing oncolytic viruses, and UroGen Pharma, which has a marketed product for low-grade NMIBC. enGene's non-viral approach is a differentiator.

Management Changes

Stakeholder Impact

• Shareholders benefit from the extended cash runway and progress in clinical trials.
• Employees may experience changes due to the CEO transition.
• Patients with NMIBC may benefit from the potential approval of EG-70.
• Investors have shown confidence in the company through the oversubscribed private financing.

Next Steps

• Announce a new indication and development plans for EG-70 in the first half of 2024.
• Release interim data from the LEGEND study in mid-2024.
• Release initial efficacy data from the LEGEND study in a BCG-naive NMIBC cohort in the second half of 2024.
• File a BLA for EG-70 in the first quarter of 2026.
• Continue the search for a new CEO.

Key Dates

Keywords

enGene, EG-70, NMIBC, bladder cancer, clinical trial, private financing, biotechnology, genetic medicines, LEGEND study, financial results